Detalhe da pesquisa
1.
CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma.
Mol Cancer
; 22(1): 64, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36998071
2.
Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus-specific T cells in the recipient: A novel strategy to limit antiviral prophylaxis.
Am J Hematol
; 98(4): 588-597, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36594185
3.
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
Am J Hematol
; 98(6): 848-856, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36880203
4.
Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
Cancer
; 128(3): 529-535, 2022 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34633671
5.
Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia.
Curr Opin Oncol
; 34(5): 531-539, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35855507
6.
Current and Emerging Therapies for Acute Myeloid Leukemia.
Cancer Treat Res
; 181: 57-73, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34626355
7.
Sizes, ratios, approximations: On what and how the ANS represents.
Behav Brain Sci
; 44: e180, 2021 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34907879
8.
Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia.
Blood
; 141(12): 1489-1493, 2023 03 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36493344
9.
Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?
Haematologica
; 104(8): 1521-1531, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31366466
10.
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study.
Am J Hematol
; 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38751104
11.
Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
Br J Haematol
; 196(6): e71-e74, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34931310
12.
High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.
Am J Hematol
; 97(5): E171-E173, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35132678
13.
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy.
Am J Hematol
; 96(5): E171-E175, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33650111
14.
Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
Leuk Lymphoma
; 65(3): 372-377, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38164785
15.
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Leukemia
; 38(4): 762-768, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38378841
16.
Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.
Blood
; 118(17): 4666-73, 2011 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-21873545
17.
Cyclin-dependent kinase-9 in B-cell malignancies: pathogenic role and therapeutic implications.
Leuk Lymphoma
; 64(12): 1893-1904, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552126
18.
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.
Leuk Lymphoma
; 64(1): 188-196, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36287540
19.
Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab.
Transplant Cell Ther
; 29(5): 314-320, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36682470
20.
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.
Transplant Cell Ther
; 29(8): 515.e1-515.e7, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37182736